The Quantity and Quality of Scientific Graphs in Pharmaceutical Advertisements
Journal Title: Journal of General Internal Medicine - Year 2003, Vol 18, Issue 4
Abstract
We characterized the quantity and quality of graphs in all pharmaceutical advertisements, in the 10 U.S. medical journals. Four hundred eighty-four unique advertisements (of 3,185 total advertisements) contained 836 glossy and 455 small-print pages. Forty-nine percent of glossy page area was nonscientific figures/images, 0.4% tables, and 1.6% scientific graphs (74 graphs in 64 advertisements). All 74 graphs were univariate displays, 4% were distributions, and 4% contained confidence intervals for summary measures. Extraneous decoration (66%) and redundancy (46%) were common. Fifty-eight percent of graphs presented an outcome relevant to the drug's indication. Numeric distortion, specifically prohibited by FDA regulations, occurred in 36% of graphs.
Authors and Affiliations
Richelle J Cooper, David L Schriger, Roger C Wallace, Vladislav J Mikulich, Michael S Wilkes
Predictors of Early Hospital Readmission in HIV-infected Patients with Pneumonia
Although hospitalization patterns have been studied, little is known about hospital readmission among HIV-infected patients in the era of highly active antiretroviral therapy. We explored the risk factors for early readm...
Residential Smoking Therapy
To evaluate a pilot 4-day residential smoking treatment program for smokers who had relapsed after participation in an outpatient smoking program.
Rapid Magnetic Resonance Imaging for Diagnosing Cancer-related Low Back Pain: A Cost-effectiveness Analysis
This study compared the relative efficiency of lumbar x-ray and rapid magnetic resonance (MR) imaging for diagnosing cancer-related low back pain (LBP) in primary care patients.
Ambulatory Internal Medicine Training: Challenges and Opportunities
Physician Specialization and Antiretroviral Therapy for HIV: Adoption and Use in a National Probability Sample of Persons Infected With HIV
Since the introduction of the first protease inhibitor in January 1996, there has been a dramatic change in the treatment of persons infected with HIV. The changing nature of HIV care has important implications for the t...